OA-98 Creating a whole that is more than the sum of its parts: an emerging collaboration between clinical trial units in UK, West and East Africa
A Zemsi, S Voller, E Ruzagira, SO Sillah, G Kimbugwe… - 2023 - gh.bmj.com
Abstracts Page 1 Methods We conducted a non-randomized, open-label, singledose, one
sequence crossover study with 2 arms. A single oral dose of 40 mg/kg PZQ followed by a daily …
sequence crossover study with 2 arms. A single oral dose of 40 mg/kg PZQ followed by a daily …
PA-213 Enhancing protocol compliance in large pragmatic drug trials implemented in resource-limited settings: experience from the PregnAnZI-2 trial in the Gambia
SO Sillah, A Zemsi, B Camara, AN Sanyang… - 2023 - gh.bmj.com
Background The PregnAnZI-2 trial was conducted in The Gambia and in Burkina Faso to
evaluate the efficacy of intrapartum azithromycin (AZI) to reduce neonatal sepsis and mortality …
evaluate the efficacy of intrapartum azithromycin (AZI) to reduce neonatal sepsis and mortality …
Evidence for an enhanced HIV/AIDS policy and care in Cameroon: proceedings of the second Cameroon HIV Research Forum (CAM-HERO) 2021
…, B Atanga, L Simo, M Bakari, A Zemsi… - Pan African Medical …, 2022 - ajol.info
To attain the HIV 95-95-95 goals by 2030 in Cameroon, high quality research to inform policy
and patient care is of utmost importance. In the context of limited workforce and resources, …
and patient care is of utmost importance. In the context of limited workforce and resources, …
[HTML][HTML] Practical Guidelines for Standardised Resolution of Important Protocol Deviations in Clinical Trials Conducted in Sub-Saharan Africa
A Zemsi, LJG Nekame, N Mohammed… - … Innovation & Regulatory …, 2024 - Springer
A clinical trial is any research on human subjects that involves an investigational medicinal
product or device. Investigational medicinal products include unlicensed drugs or drugs used …
product or device. Investigational medicinal products include unlicensed drugs or drugs used …
Outcomes of the first meeting of the CAMEROON HIV RESEARCH FORUM (CAM-HERO)
…, B Atanga, L Simo, J Ateudjieu, A Zemsi… - Pan African Medical …, 2021 - ajol.info
Research is a vital component for the development of any country. In Cameroon, HIV
Operational research is rapidly growing, however, it faces some intractable problems which can …
Operational research is rapidly growing, however, it faces some intractable problems which can …
Electrocardiographic safety of daily hydroxychloroquine 400mg plus azithromycin 250mg as an ambulatory treatment for COVID-19 patients in Cameroon
…, JN Tochie, A Zemsi, L Fomete, S Lekelem, S Zemsi… - medRxiv, 2020 - medrxiv.org
Objective To determine the early electrocardiographic changes in a cohort of ambulatory
cameroonian COVID-19 patients treated with hydroxychloroquine and Azithromycin. Design …
cameroonian COVID-19 patients treated with hydroxychloroquine and Azithromycin. Design …
[PDF][PDF] Doxycycline vs Hydroxychloroquine+ Azithromycin in the Management of COVID-19 Patients: An Open-Label Randomized Clinical Trial in Sub-Saharan Africa …
E Sobngwi, S Zemsi, M Guewo, JC Katte, C Kouanfack… - Cureus, 2023 - cureus.com
Objective We aimed to compare the safety and efficacy of a doxycycline-based regimen against
Cameroon National Standard Guidelines (hydroxychloroquine plus azithromycin) for the …
Cameroon National Standard Guidelines (hydroxychloroquine plus azithromycin) for the …
[HTML][HTML] Research priorities for accelerating the achievement of three 95 HIV goals in Cameroon: a consensus statement from the Cameroon HIV Research Forum …
…, FN Tabala, B Atanga, L Simo, A Zemsi… - Pan African Medical …, 2021 - ajol.info
Introduction: the Treat-All remains the globally endorsed approach to attain the 95-95-95
targets and end the AIDS pandemic by 2030, but requires some country-level contextualization. …
targets and end the AIDS pandemic by 2030, but requires some country-level contextualization. …
Doxycycline is a safe alternative to Hydroxychloroquine+ Azithromycin to prevent clinical worsening and hospitalization in mild COVID-19 patients: An open label …
E Sobngwi, S Zemsi, M Guewo-Fokeng, JC Katte… - medRxiv, 2021 - medrxiv.org
Objective We aimed to compare the safety and efficacy of a doxycycline-based regimen
against the national standard guidelines (Hydroxychloroquine plus Azithromycin) for the …
against the national standard guidelines (Hydroxychloroquine plus Azithromycin) for the …
Electrocardiographic safety of daily Hydroxychloroquine 400mg plus Azithromycin 250mg as an ambulatory treatment for COVID-19 patients in Cameroon.
…, JN Tochie, A Zemsi, L Fomete, S Lekelem, S Zemsi… - 2020 - pesquisa.bvsalud.org
ObjectiveTo determine the early electrocardiographic changes in a cohort of ambulatory
cameroonian COVID-19 patients treated with hydroxychloroquine and Azithromycin. …
cameroonian COVID-19 patients treated with hydroxychloroquine and Azithromycin. …